-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40

Benzinga·08/11/2026 14:48:06
Listen to the news
JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target from $44 to $40.